Qurient Announces Publication in New England Journal of Medicine of Phase 2 Data for Telacebec, a First-in-Class Antibiotic for the Treatment of Tuberculosis
Clinical data supports continued development of telacebec toward the first universal regimen to overcome tuberculosis…